知搜-全球专利检索

  1. 登录
  2. 注册

搜索结果

105 条记录 (耗时 0.034 秒)

    Annexin Proteins and Autoantibodies As Serum Markers For Cancer
    61.
    发明申请
    Annexin Proteins and Autoantibodies As Serum Markers For Cancer 有权
    膜联蛋白和自身抗体作为血清标志物用于癌症

    公开(公告)号：US20100330587A1

    公开(公告)日：2010-12-30

    申请号：US12813070

    申请日：2010-06-10

    申请人： Samir M. Hanash ,  David Misek ,  Robert Hinderer ,  David Beer ,  Franck Brichory

    发明人： Samir M. Hanash ,  David Misek ,  Robert Hinderer ,  David Beer ,  Franck Brichory

    IPC分类号： G01N33/53

    CPC分类号： G01N33/57488 ,  A61K39/0011 ,  G01N33/57423 ,  G01N33/57484 ,  G01N2333/4718 ,  G01N2800/52

    摘要： The present invention relates to screening methods for diagnosis, prognosis, or susceptibility to cancer in a subject by means of detecting the presence of serum autoantibodies to specific annexin protein antigens in sera from subjects. The present invention also provides screening methods for diagnosis and prognosis of cancer in a subject by means of detecting increased expression levels of annexin proteins in biological samples of the subject. The method of the invention can also be used to identify subjects at risk for developing cancer. The method of the invention involves the use of subject derived biological samples to determine the occurrence and level of expression of annexin proteins or expression of annexin derived peptides or antigens, and/or the occurrence and level of circulating autoantibodies to specific annexin protein antigens. The present invention further provides for kits for carrying out the above described screening methods. Such kits can be used to screen subjects for increased levels of annexin proteins, or for the detection of autoantibodies to annexin proteins, as a diagnostic, predictive or prognostic indicator of cancer.

    摘要翻译： 本发明涉及通过检测来自受试者的血清中特异性膜联蛋白抗原的血清自身抗体的存在而在受试者中诊断，预后或易感性的筛选方法。 本发明还提供了通过检测受试者生物样品中膜联蛋白的增加的表达水平来检测受试者中癌症的诊断和预后的筛选方法。 本发明的方法还可以用于鉴定患有癌症风险的受试者。 本发明的方法涉及使用受试者衍生的生物样品来确定膜联蛋白的表达的发生和水平或膜联蛋白衍生的肽或抗原的表达，和/或对特定的膜联蛋白抗原的循环自身抗体的发生和水平。 本发明还提供了用于实施上述筛选方法的试剂盒。 这样的试剂盒可用于筛选受试者增加的膜联蛋白水平，或用于检测对膜联蛋白的自身抗体，作为癌症的诊断性，预测性或预后指标。

    USE OF FLOW-CYTROMETRIC ANALYSIS TO OPTIMIZE CELL BANKING STRATEGIES FOR CHO CELLS
    63.
    发明申请
    USE OF FLOW-CYTROMETRIC ANALYSIS TO OPTIMIZE CELL BANKING STRATEGIES FOR CHO CELLS 审中-公开
    流式细胞分析法优化CHO细胞细胞储存策略的应用

    公开(公告)号：US20100086947A1

    公开(公告)日：2010-04-08

    申请号：US12491677

    申请日：2009-06-25

    申请人： Hitto KAUFMANN ,  Juergen FIEDER ,  Ralf OTTO

    发明人： Hitto KAUFMANN ,  Juergen FIEDER ,  Ralf OTTO

    IPC分类号： G01N33/53 ,  C12Q1/02

    CPC分类号： G01N33/56966 ,  G01N2333/4718

    摘要： Production of biopharmaceuticals from CHO cells requires generation of master-, working- and post-production cell banks of high quality, partly under GMP conditions. An optimal cryopreservation strategy is needed for each new production cell line, particularly with regard to the desire to establish production processes that are completely devoid of serum or even any animal components and to ensure robust thaw performance for reliable production. Here we describe a novel strategy employing flow cytometric (FC) analysis of Annexin V-stained cells for high-throughput characterization of CHO cell banks. Our data show that this method enables evaluation of a cryopreservation procedure just 6 h after thaw.

    摘要翻译： 从CHO细胞生产生物药物需要生产高质量的母体，工作和后期生产细胞库，部分是在GMP条件下生产。 每个新的生产细胞系都需要最佳的冷冻保存策略，特别是关于建立完全没有血清或甚至任何动物成分的生产过程的愿望，并确保可靠生产的强大的解冻性能。 在这里，我们描述了一种采用流式细胞术（FC）分析Annexin V染色细胞用于CHO细胞库的高通量表征的新策略。 我们的数据显示，这种方法能够在融化6小时后进行冷冻保存程序的评估。

    IDENTIFYING CORONARY OR SOFT TISSUE CALCIFICATION
    64.
    发明申请
    IDENTIFYING CORONARY OR SOFT TISSUE CALCIFICATION 审中-公开
    识别冠状或软组织计算

    公开(公告)号：US20090311715A1

    公开(公告)日：2009-12-17

    申请号：US12435734

    申请日：2009-05-05

    申请人： Whyte G. Owen ,  Virginia M. Miller ,  Muthuvel Jayachandran

    发明人： Whyte G. Owen ,  Virginia M. Miller ,  Muthuvel Jayachandran

    IPC分类号： G01N33/53

    CPC分类号： G01N33/567 ,  G01N33/586 ,  G01N33/6893 ,  G01N2333/4718 ,  G01N2333/70596 ,  G01N2800/32 ,  G01N2800/50

    摘要： This document relates to methods and materials involved in identifying calcification (e.g., coronary calcification or soft tissue calcification) in mammals and assessing thrombotic risk in mammals. For example, methods and materials involved in using microvesicles as a marker to determine whether or not a mammal (e.g., a human) has calcification or an elevated risk of thrombosis are provided. In addition, methods and materials for determining the amount and source of microvesicles are provided.

    摘要翻译： 本文件涉及涉及确定哺乳动物钙化（例如冠状动脉钙化或软组织钙化）和评估哺乳动物血栓形成风险的方法和材料。 例如，提供了使用微泡作为标记物来确定哺乳动物（例如人）是否具有钙化或升高的血栓形成风险的方法和材料。 另外，提供了确定微泡量和来源的方法和材料。

    Use of flow-cytrometric analysis to optimize cell banking strategies for CHO cells
    66.
    发明授权
    Use of flow-cytrometric analysis to optimize cell banking strategies for CHO cells 有权
    使用流式细胞分析法优化CHO细胞的细胞银行策略

    公开(公告)号：US07569339B2

    公开(公告)日：2009-08-04

    申请号：US11270236

    申请日：2005-11-09

    申请人： Hitto Kaufmann ,  Juergen Fieder ,  Ralf Otto

    发明人： Hitto Kaufmann ,  Juergen Fieder ,  Ralf Otto

    IPC分类号： C12Q1/00 ,  G01N33/48 ,  C12N5/02

    CPC分类号： G01N33/56966 ,  G01N2333/4718

    摘要： Production of biopharmaceuticals from CHO cells requires generation of master-, working- and post-production cell banks of high quality, partly under GMP conditions. An optimal cryopreservation strategy is needed for each new production cell line, particularly with regard to the desire to establish production processes that are completely devoid of serum or even any animal components and to ensure robust thaw performance for reliable production. Here we describe a novel strategy employing flow cytometric (FC) analysis of Annexin V-stained cells for high-throughput characterization of CHO cell banks. Our data show that this method enables evaluation of a cryopreservation procedure just 6 h after thaw.

    摘要翻译： 从CHO细胞生产生物药物需要生产高质量的母体，工作和后期生产细胞库，部分是在GMP条件下生产。 每个新的生产细胞系都需要最佳的冷冻保存策略，特别是关于建立完全没有血清或甚至任何动物成分的生产过程的愿望，并确保可靠生产的强大的解冻性能。 在这里，我们描述了一种采用流式细胞术（FC）分析Annexin V染色细胞用于CHO细胞库的高通量表征的新策略。 我们的数据显示，这种方法能够在融化6小时后进行冷冻保存程序的评估。

    Overexpression of mammaglobin B in ovarian and endometrial tumors - a new diagnostic and therapeutic marker
    68.
    发明申请
    Overexpression of mammaglobin B in ovarian and endometrial tumors - a new diagnostic and therapeutic marker 审中-公开
    乳腺球蛋白B在卵巢和子宫内膜肿瘤中的过表达 - 一种新的诊断和治疗标记

    公开(公告)号：US20080199885A1

    公开(公告)日：2008-08-21

    申请号：US11709014

    申请日：2007-02-21

    申请人： Alessandro D. Santin

    发明人： Alessandro D. Santin

    IPC分类号： A61K38/02 ,  A61P35/00 ,  G01N33/53

    CPC分类号： G01N33/574 ,  A61K38/02 ,  A61K39/0011 ,  A61K2039/5154 ,  G01N33/57449 ,  G01N2333/4718

    摘要： The invention involves the discovery that the mammaglobin B gene is the single most overexpressed gene in primary ovarian serous papillary cancer over normal ovarian epithelium among over 14,000 genes tested. It is expressed over 800-fold higher in primary ovarian tumors than normal ovarian epithelium. Mammaglobin B gene expression was detected in endometrioid, mucinous, undifferentiated, serous papillary, clear cell, and mixed histology ovarian tumors. The protein can be found in blood and ascites fluid, and a simple blood test for the presence of mammaglobin B protein can provide early detection of ovarian and other cancers. The invention provides a method of screening for cancer involving detecting mammaglobin B in a fluid sample.

    摘要翻译： 本发明涉及发现，在超过14,000个测试的基因中，乳腺球蛋白B基因是原代卵巢浆液性乳头状癌中超过正常卵巢上皮的单一最高表达基因。 原代卵巢肿瘤比正常卵巢上皮表达高出800倍以上。 在子宫内膜样，粘液性，未分化，浆液性乳头状，透明细胞和混合组织学卵巢肿瘤中检测到乳腺珠蛋白B基因表达。 蛋白质可以在血液和腹水中发现，并且用于乳腺球蛋白B蛋白存在的简单血液检查可以提供卵巢癌和其他癌症的早期检测。 本发明提供了一种筛选癌症的方法，涉及检测流体样品中的乳腺球蛋白B.

    ANNEXIN PROTEINS AND AUTOANTIBODIES AS SERUM MARKERS FOR CANCER
    69.
    发明申请
    ANNEXIN PROTEINS AND AUTOANTIBODIES AS SERUM MARKERS FOR CANCER 审中-公开
    作为癌症血清标记的新蛋白和自动体

    公开(公告)号：US20060275845A1

    公开(公告)日：2006-12-07

    申请号：US11425439

    申请日：2006-06-21

    申请人： Samir HANASH ,  David Misek ,  Robert Hinderer ,  David Beer ,  Franck Brichory

    发明人： Samir HANASH ,  David Misek ,  Robert Hinderer ,  David Beer ,  Franck Brichory

    IPC分类号： G01N33/574

    CPC分类号： G01N33/57488 ,  A61K39/0011 ,  G01N33/57423 ,  G01N33/57484 ,  G01N2333/4718 ,  G01N2800/52

    摘要： The present invention relates to screening methods for diagnosis, prognosis, or susceptibility to cancer in a subject by means of detecting the presence of serum autoantibodies to specific annexin protein antigens in sera from subjects. The present invention also provides screening methods for diagnosis and prognosis of cancer in a subject by means of detecting increased expression levels of annexin proteins in biological samples of the subject. The method of the invention can also be used to identify subjects at risk for developing cancer. The method of the invention involves the use of subject derived biological samples to determine the occurrence and level of express on of annexin proteins or expression of annexin derived peptides or antigens, and/or the occurrence and level of circulating autoantibodies to specific annexin protein antigens. The present invention further provides for kits for carrying out the above described screening methods. Such kits can be used to screen subjects for increased levels of annexin proteins, or for the detection of autoantibodies to annexin proteins, as a diagnostic, predictive or prognostic indicator of cancer.

    摘要翻译： 本发明涉及通过检测来自受试者的血清中特异性膜联蛋白抗原的血清自身抗体的存在而在受试者中诊断，预后或易感性的筛选方法。 本发明还提供了通过检测受试者生物样品中膜联蛋白的增加的表达水平来检测受试者中癌症的诊断和预后的筛选方法。 本发明的方法还可以用于鉴定患有癌症风险的受试者。 本发明的方法涉及使用受试者衍生的生物样品来确定膜联蛋白的表达或膜联蛋白衍生的肽或抗原的表达的发生和水平，和/或特定膜联蛋白抗原的循环自身抗体的发生和水平。 本发明还提供了用于实施上述筛选方法的试剂盒。 这样的试剂盒可用于筛选受试者增加的膜联蛋白水平，或用于检测对膜联蛋白的自身抗体，作为癌症的诊断性，预测性或预后指标。